Search Within

Neha Sanat Korde

Formats
  1. Meeting Abstract (150)
  2. Journal Article (63)
  3. Research Letter (7)
  4. Review (3)
  5. Correspondence (2)
  6. Conference Paper (1)
Groups
  1. Center for Hematologic Malignancies (226)
  2. Department of Medicine (226)
  3. Hematologic Malignancies, Division of (226)
  4. Myeloma (226)
  5. Survivorship Research (226)
  6. Hematologic Malignancies Research (205)

More Groups

People
  1. Sham Mailankody (181)
  2. Alexander Lesokhin (162)
  3. Hani Hassoun (157)
  4. Malin Hultcrantz (145)
  5. Sergio Giralt (138)
  6. Heather Landau (137)

More People

Years
  1. 2025 (2)
  2. 2024 (36)
  3. 2023 (40)
  4. 2022 (34)
  5. 2021 (15)
  6. 2020 (14)

More Years

Publications
  1. Blood (83)
  2. Clinical Lymphoma, Myeloma and Leukemia (47)
  3. Journal of Clinical Oncology (17)
  4. Leukemia and Lymphoma (11)
  5. Biology of Blood and Marrow Transplantation (7)
  6. Blood Cancer Journal (7)

More Publications

Publishers
  1. American Society of Hematology (89)
  2. Elsevier Inc. (60)
  3. American Society of Clinical Oncology (17)
  4. Nature Publishing Group (13)
  5. Taylor & Francis Group (11)
  6. Ferrata Storti Foundation (7)

More Publishers

Results (226)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Interim results of a phase 2 trial of isatuximab-lenalidomide for patients with High-Risk Smoldering Multiple Myeloma
    Meeting Abstract

    Thomas, S.; Manasanch, E.; Korde, N.; Lee, H.; Jagannath, S.; Becnel, M.; Kaufman, G.; Patel, K.; Iyer, S.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Para-medullary (PMD) and extra-medullary (EMD) myeloma demonstrate increased copy number aberration, mutational burden, structural variants and genomic complexity compared to marrow-based myeloma
    Meeting Abstract

    Maclachlan, K.; GarceĢs, J. J.; Shekarkhand, T.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Tan, C.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Maintenance therapy cessation for multiple myeloma patients with three-year sustained mrd negative remissions
    Meeting Abstract

    Korde, N.; Hassoun, H.; Landau, H.; Hamid, S.; Derkach, A.; Hultcrantz, M.; Mailankody, S.; Tan, C.; Shah, U.; Maclachlan, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • A phase 1 first-in-human study of the MCL-1 inhibitor AZD5991 in patients with relapsed/refractory hematologic malignancies
    Journal Article

    Desai, P.; Lonial, S.; Cashen, A.; Kamdar, M.; Flinn, I.; O'Brien, S.; Garcia, J. S.; Korde, N.; Moslehi, J.; Wey, M.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Genomic profiling to contextualize the results of intervention for smoldering multiple myeloma
    Journal Article

    Kazandjian, D.; Diamond, B.; Papadimitriou, M.; Hill, E.; Sklavenitis-Pistofidis, R.; Ziccheddu, B.; Blaney, P.; Chojnacka, M.; Durante, M.; Maclachlan, K.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma
    Research Letter

    Hultcrantz, M.; Hassoun, H.; Korde, N.; MacLachlan, K.; Mailankody, S.; Patel, D.; Shah, U. A.; Tan, C. R.; Chung, D. J.; Lahoud, O. B.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • Efficacy, safety, and determination of RP2D of ABBV-383, a BCMA bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Valdes, C. R.; Voorhees, P. M.; D'Souza, A.; Chung, A.; Tuchman, S.; Safah, H.; McKay, J. T.; Weisel, K. C.; Teipel, R.; Korde, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Correlative biomarker analyses for optimal therapeutic dose determination of ABBV-383, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Ahsan, A.; Mantis, C.; Luo, X.; Zhang, C. C.; Valdes, C. R.; Voorhees, P. M.; D'Souza, A.; Chung, A.; Tuchman, S.; Safah, H.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Real-world schedule de-escalation of teclistamab in patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Tan, C. R. C.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; Shah, G. L.; Scordo, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Clinical outcomes of retreatment with daratumumab-based regimens in anti-CD38 refractory multiple myeloma
    Meeting Abstract

    Tan, C. R. C.; Rueda, C.; Shekarkhand, T.; Derkach, A.; Korde, N.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save